Clozapine - CAS 5786-21-0
Catalog number: 5786-21-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Dopamine Receptor
Clozapine is an atypical antipsychotic drug by acting as a 5-HT antagonist, used in the treatment of schizophrenia.
Publictions citing BOC Sciences Products
  • >> More
HF 1854, LX 100-129
1.Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea.
Sinha S1, Simlai J2, Praharaj SK3. Curr Drug Saf. 2016 Apr 26. [Epub ahead of print]
Clozapine is the antipsychotic of choice for resistant schizophrenia, but its widespread use is limited by adverse effects. Sialorrhea is a common and troublesome adverse effect seen with clozapine which leads to poor compliance. Several treatment strategies are advocated, no single treatment is considered superior. Amitriptyline, a tricyclic antidepressant, has been found to be useful for clozapine-associated sialorrhea at 87-100 mg per day. We report the effect of very low dose amitriptyline (10 mg per day) in a patient with clozapine-associated sialorrhea. There was rapid and complete resolution of sialorrhea after three days without any emergent adverse effect.
2.Use of Clozapine for Borderline Personality Disorder: A Case Report.
Amamou B1, Salah WB1, Mhalla A1, Benzarti N1, Elloumi H1, Zaafrane F1, Gaha L1. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):226-8. doi: 10.9758/cpn.2016.14.2.226.
Patients with borderline personality disorder (BPD) show significant impairment in functioning, particularly in the interpersonal and social domains. Prior reports suggest that clozapine may be effective in the management of BPD. We present the case of a patient with BPD who experienced persistent suicidal ideation and was treated with clozapine at a state psychiatric hospital. After treatment failure with other psychotropic medications, clozapine medication was initiated; not only did suicidal ideation cease, but social and professional functioning also greatly improved to the point of no longer requiring intensive levels of observation or restrictive procedures. Clozapine appears to be efficacious in the management of suicide attempts and self-injurious behavior. Moreover, it appears to be promising as a therapeutic measure for ameliorating the global functioning of patients with severe BPD. Larger, randomized, blinded, and controlled prospective studies are needed to confirm these findings and to determine optimal dosage.
3.Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature.
Singh A1, Grover S1, Malhotra P2, Varma SC2. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):212-7. doi: 10.9758/cpn.2016.14.2.212.
Agranulocytosis as a side effect of clozapine has been reported to be associated with initial phases of treatment, i.e., first six months. Agranulocytosis with clozapine during the initial phases of treatment has been linked to genetic vulnerability in the form of variations in the human leukocyte-antigen haplotypes. However, there is limited literature on late onset agranulocytosis with clozapine and this has very rarely been linked to human leukocyte-antigen haplotypes vulnerability. In this report we review the existing data on late onset agranulocytosis with clozapine and describe the case of a young man, who developed agranulocytosis with clozapine after 35 months of treatment and was found to have genetic vulnerability in form of being positive for HLA DR4. This case highlights underlying autoimmune immune mechanism in clozapine-induced agranulocytosis and the need for frequent blood count monitoring on clozapine even after the initial 6 months of starting treatment especially in patients with genetic vulnerability to develop this condition.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


(CAS: 73220-03-8)

Remoxipride is a selective dopamine D2 receptor antagonist. It shows selectivity over D3 and D4 receptors with Ki values are ~ 300nM for D2 receptor, ~ 1600nM f...

CAS 2376-65-0 Fluphenazine decanoate dihydrochloride

Fluphenazine decanoate dihydrochloride
(CAS: 2376-65-0)

Fluphenazine is a potent antipsychotic that acts by inhibiting dopamine receptors (Ki values 0.2 nM, 0.11 nM, and 2.0nM for D2, D3, and 5-HT2 receptors, respect...

CAS 839712-12-8 Cariprazine

(CAS: 839712-12-8)

Cariprazine is an orally active D2/D3 dopamine receptor antagonist exhibits high selectivity and affinity to dopamine D3(Ki=0.09 nM) and D2 (Ki=0.5 nM) receptor...

CAS 161757-96-6 (R)-PPHT hydrochloride

(R)-PPHT hydrochloride
(CAS: 161757-96-6)

(R)-PPHT hydrochloride is a potent and selective D2 agonist.

CAS 1135278-61-3 3'-Fluorobenzylspiperone maleate

3'-Fluorobenzylspiperone maleate
(CAS: 1135278-61-3)

3'-Fluorobenzylspiperone maleate is a potent and selective ligand for the dopamine D2 receptor (Ki = 0.023 nM), displaying 2.5-fold greater affinity for D2 and ...

CAS 179386-44-8 Sumanirole maleate

Sumanirole maleate
(CAS: 179386-44-8)

Sumanirole maleate, also referred as PNU 95666E or U95666E, is a high affinity D2 receptor full agonist that shows >200-fold selectivity over dopamine receptor ...

CAS 182210-73-7 (R)-5-Hydroxy-DPAT hydrobromide

(R)-5-Hydroxy-DPAT hydrobromide
(CAS: 182210-73-7)

A weak dopamine D2 receptor antagonist.

CAS 58349-17-0 (S)-(-)-5-Methoxy-2-Aminotetraline hydrochloride

(S)-(-)-5-Methoxy-2-Aminotetraline hydro
(CAS: 58349-17-0)

(S)-(-)-5-Methoxy-2-Aminotetraline hydrochloride is a dopamine receptor agonist as a therapy for Parkinson’s disease.

CAS 200954-39-8 Dilept

(CAS: 200954-39-8)

Dilept is an antagonist of neurotensin (NT) and dopamine (DA) receptor used to mitigate positive and negative symptoms of schizophrenia.

CAS 152886-85-6 U91356

(CAS: 152886-85-6)

U91356 exhibits good dopaminergic agonist activity, and has improved metabolic stability and oral bioavailability in the rat and monkey.

CAS 66644-81-3 Veralipride

(CAS: 66644-81-3)

Veralipride is a D2 receptor antagonist in the hypothalamic system and has a half-life of approximately 12 hours. Veralipride is highly active on the neurotrans...

CAS 854924-64-4 ST 198

ST 198
(CAS: 854924-64-4)

ST 198 is a dopamine D3 receptor antagonist.

CAS 53-60-1 Promazine Hydrochloride

Promazine Hydrochloride
(CAS: 53-60-1)

Promazine Hydrochloride is a phenothiazine used in short-term treatment of disturbed behavior and as an antiemetic.

CAS 1347744-96-0 A 412997 dihydrochloride

A 412997 dihydrochloride
(CAS: 1347744-96-0)

A 412997 dihydrochloride is a potent and selective agonist for the dopamine D4 receptor (Ki = 7.9 and 12.1 nM for human D4 and rat D4, receptors) with no activi...


RuBi-Dopa is RuBi-caged dopamine. RuBi-Dopa has a high uncaging efficiency and can be released with visible (blue-green) and IR light in a two-photon regime. It...

CAS 96333-05-0 N 0432 hydrobromide

N 0432 hydrobromide
(CAS: 96333-05-0)

N 0432 hydrobromide is a monoamine oxidase (MAO) inhibitor and a dopamine agonist.

CAS 113-59-7 Chlorprothixene

(CAS: 113-59-7)

Chlorprothixene has strong binding affinities to dopamine and histamine receptors, such as D1, D2, D3, D5, H1, 5-HT2, 5-HT6 and 5-HT7, with Ki of 18 nM, 2.96 nM...

CAS 115092-85-8 Carmoxirole hydrochloride

Carmoxirole hydrochloride
(CAS: 115092-85-8)

The hydrochloride salt form of Carmoxirole , which is a selective, peripherally acting dopamine D2 receptor agonist and exhibits antihypertensive activities in ...

CAS 13575-86-5 6,7-Dihydroxy-2-aminotetraline hydrobromide

6,7-Dihydroxy-2-aminotetraline hydrobrom
(CAS: 13575-86-5)

6,7-Dihydroxy-2-Aminotetraline hydrobromide is a dopamine receptor agonist.

CAS 71787-90-1 PPHT hydrochloride

PPHT hydrochloride
(CAS: 71787-90-1)

PPHT hydrochloride is a potent and selective D2 agonist.

Chemical Structure

CAS 5786-21-0 Clozapine

Quick Inquiry

Verification code

Featured Items